EBS
NYSEEmergent BioSolutions Inc.
News · 26 weeks72+500%
2026-03-012026-08-23
Mix1690d
- Insider6(38%)
- Other5(31%)
- SEC Filings2(13%)
- Earnings2(13%)
- Analyst1(6%)
Latest news
25 items- ANALYSTAnalyst resumed coverage on Emergent BioSolutionsAnalyst resumed coverage of Emergent BioSolutions with a rating of Underweight
- SECSEC Form SCHEDULE 13G filed by Emergent BioSolutions Inc.SCHEDULE 13G - Emergent BioSolutions Inc. (0001367644) (Subject)
- INSIDERNew insider Duatschek Stephanie claimed ownership of 197,416 shares (SEC Form 3)3 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- SECEmergent BioSolutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
- PREmergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security EnvironmentGAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning. In a recent event by the G
- PREmergent BioSolutions Reports Second Quarter 2026 Financial ResultsSecond Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3 million non-cash impairment chargeSecond Quarter 2026 Adjusted Net Income of $30.9 million improved 134% versus prior yearSecond Quarter 2026 Gross Margin % of 50% and Adjusted Gross Margin % of 58%, an expansion of 1400 bps and 900 bps, respectively, versus prior yearSecond Quarter 2026 Adjusted EBITDA of $96.5 million and Adjusted EBITDA Margin of 41%, an improvement of 1,800 bps versus prior yearRestructuring business operations to align resourcing to current needs; expected to result in annu
- PREmergent BioSolutions to Report Second Quarter 2026 Financial Results on August 5, 2026GAITHERSBURG, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Wednesday, August 5, 2026, at 5:00 p.m. eastern time to discuss the financial results for the second quarter of 2026. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call can
- INSIDERSVP, Products Business Williams Paul Anthony sold $25,200 worth of shares (3,000 units at $8.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 159,098 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- SECEmergent BioSolutions Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
- PREmergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. GovernmentGAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries as well as diluent replacement lots for smallpox preparedness and response needs. Deliveries are expected to begin this month. "This new contract modification for ACAM2000® underscores the U.S. government’s continued focus on biodefense preparedness and reflects Emergent’s longstanding role to collaborate an
- INSIDERSVP, Products Business Williams Paul Anthony covered exercise/tax liability with 694 shares, decreasing direct ownership by 0.43% to 162,098 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDEREVP, Chief Financial Officer Lindahl Richard S covered exercise/tax liability with 3,964 shares, decreasing direct ownership by 1% to 374,083 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDEREVP, Quality & Ethics, and CPL Glessner Coleen covered exercise/tax liability with 2,018 shares, decreasing direct ownership by 0.99% to 202,201 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDERSVP, Bioservices Hartzel William covered exercise/tax liability with 1,741 shares, decreasing direct ownership by 0.93% to 185,558 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- PREmergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day to Help Save Lives from Opioid OverdoseGAITHERSBURG, Md., June 04, 2026 (GLOBE NEWSWIRE) -- In honor of National Naloxone Awareness Day on June 6th, Emergent BioSolutions Inc. (NYSE:EBS) is teaming up with Victoria's Voice Foundation – which launched the awareness day with bipartisan congressional support – to spread awareness and encourage action against the ongoing opioid epidemic. Serving as a tribute to Victoria Siegel and all those lost to overdoses, Victoria's Voice is continuing the "Shine. Wear. Share. Care." Campaign, which promotes education and preparedness by distributing purple light bulbs (Shine), wearable promotional items (Wear), encouraging social media participation via QR codes with #sharenaloxone (Share), an
- PREmergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense StrategyGAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the Administration for Strategic Preparedness and Response (ASPR), a division of the United States Department of Health and Human Services (HHS), for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]. The modification has been made to the existing 10-year contract with ASPR (75A50119C00075) whereby Emergent will supply BAT®, an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G
- PREmergent BioSolutions to Participate in Upcoming Investor ConferencesGAITHERSBURG, Md., May 20, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of the company's senior management team will participate in the following investor conferences: Goldman Sachs 11th Annual Leveraged Finance and Credit Conference, May 27-29Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, May 28Jefferies Global Healthcare Conference, June 2-4 June 3: presentation and webcast, 1:20-1:50 p.m. eastern time, register here. Goldman Sachs 47th Annual Global Healthcare Conference, June 8-10 June 8: presentation and webcast, 2:00-3:00 p.m. eastern time, register here. Please contact a conference repr
- PREmergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food and Drug Authority (SFDA) has approved the registration of ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live], for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection. This follows Emergent's recent announcement that Singapore's Health Sciences Authority (HSA) has approved an expanded indication for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] to include prevention of mpox disease in adults determined to be at high risk for mpox infection. "We are pleased to
- INSIDERDirector Dayal Sujata Tyagi was granted 25,344 shares and sold $115,610 worth of shares (13,761 units at $8.40) as part of a pre-agreed trading plan, increasing direct ownership by 13% to 100,563 units (SEC Form 4) (withholding obligation)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDERDirector Degolyer Donald W was granted 25,344 shares and sold $129,994 worth of shares (15,481 units at $8.40) as part of a pre-agreed trading plan, increasing direct ownership by 8% to 129,721 units (SEC Form 4) (withholding obligation)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDERDirector Katkin Keith was granted 25,344 shares and sold $128,183 worth of shares (15,481 units at $8.28) as part of a pre-agreed trading plan, increasing direct ownership by 11% to 96,294 units (SEC Form 4) (withholding tax)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDERDirector White Marvin L was granted 25,344 shares, increasing direct ownership by 29% to 113,839 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDERDirector Fowler John D Jr was granted 25,344 shares, increasing direct ownership by 506% to 30,350 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDERDirector Richard Ronald was granted 25,344 shares, increasing direct ownership by 26% to 123,761 units (SEC Form 4)4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
- INSIDERDirector Zoon Kathryn C sold $144,453 worth of shares (17,202 units at $8.40) as part of a pre-agreed trading plan and was granted 25,344 shares, increasing direct ownership by 11% to 79,941 units (SEC Form 4) to cover withholding tax4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
EBS FAQ
7 questionsWhat does Emergent BioSolutions Inc. do?
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine...Where does EBS stock trade?
Emergent BioSolutions Inc. (EBS) is listed on NYSE.What sector and industry is EBS in?
Emergent BioSolutions Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Emergent BioSolutions Inc. go public?
Emergent BioSolutions Inc. (EBS) completed its IPO in 2006.What are analysts saying about EBS?
Emergent BioSolutions Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Underweight on 2026-08-21. Recent price targets range from $500.00 to $2200.00.What companies are similar to EBS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EBS side-by-side with any of them on Quantisnow.How can I track EBS on Quantisnow?
Quantisnow aggregates Emergent BioSolutions Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EBS to receive live email and push alerts on every new disclosure.